PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Is the Life Sciences Strategy Too Ambitious for the NHS? Lords To Hear Evidence

The House of Lords Science and Technology Committee will continue taking evidence for its inquiry into Life Sciences and the Industrial Strategy on Tuesday 7 November. The Committee will question representatives from NHS England, Innovate UK and Catapults.
Sir John Bell’s life science strategy sets out the important role the NHS must play in the UK life sciences sector, including faster adoption of innovative new technologies and treatments. However, there are concerns that the NHS is not ready for this level of innovation with issues including funding, resources and the culture of the NHS.
The Committee will explore with the witnesses their views on how NHS England can help successfully implement the objectives of the strategy.
The first evidence session will begin at 10.10 am and the Committee will question:
  • Dr Ruth McKernan, Chief Executive, Innovate UK
  • Chris Molloy, CEO, Medicines Discovery Catapult
  • Keith Thompson, CEO, Cell and Gene Therapy Catapult
  • Professor Graham Hillier, Strategy and Futures Director, Centre for Process Innovation, High Value Manufacturing Catapult
The second evidence session will begin at 11.10 am:
  • Ian Dodge, National Director for Strategy and Innovation
  • Professor Mike Hannay, Director of the East Midlands Academic Health Science Network
  • Professor Keith McNeil, Chief Clinical Information Officer Health and Social Care
Topics likely to be covered across the sessions include:
  • The role of the witnesses’ organisations in the implementation of the strategy
  • How academics and NHS clinicians can better collaborate on important research
  • The role of commissioners in adoption of innovations and whether NHS Trusts should be offered financial incentives for the adoption of innovations
  • How the relationship between UKRI and Innovate UK will help with innovation and commercialisation of science
The evidence session will begin at 10.10 am on Tuesday 7 November in Committee Room 4A of the House of Lords.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026